PFS was examining time to progression of any metastatic tumour i.e within liver and/or outside.
If 40% of subjects had tumours outside the liver, at the time any of those increased in size (on CT scan) they are deemed to have had a progression.
But why wouldn't the tumours outside the liver continue to grow at the same rate? Those tumours got the same chemo but weren't exposed to the Sirspheres?
If, and this is only if, the overall survival figures for the sirspheres patients were better because the liver tumours were smaller, then this trial report has caused some shareholders who sold some significant damage. And it is still entirely possible that OS is better without any benefit in PFS outside the liver.
SRX Price at posting:
$17.53 Sentiment: Hold Disclosure: Held
